Ligand-based virtual screening (LBVS) has rarely been tested as a method for discovering new structural scaffolds for PET radioligand development. This study used LBVS to discover potential chemotype leads for developing radioligands for PET imaging of tauopathies. ZINC12, a free database of over 12 million commercially available compounds, was searched to discover novel scaffolds based on similarities to four query compounds. Thirteen high-ranking hits were purchased and assayed for their ability to compete against three tritiated radioligands at their distinct binding sites in Alzheimer's disease brain tissue. Three hits were 2-substituted 6-methoxy naphthalenes. Synthetic elaboration of this new chemotype yielded three new ligands (, , and ) with high affinity for the [H] (flortaucipur) neurofibrillary tangle binding site. Compound showed remarkably high affinity (, 7 nM) and other desirable properties for a candidate PET radioligand, including low topological polar surface area, moderate computed log , and amenability for labeling with carbon-11. LBVS appears to be uniquely valuable for discovering new chemotypes for candidate PET radioligands.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acs.jmedchem.4c00934 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Surgical and multimodal approaches to right-sided cardiac tumours.
Curr Opin Cardiol
January 2025
Division of Cardiac Surgery, Peter Munk Cardiac Centre, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada.
Purpose Of Review: Cardiac tumours present significant clinical challenges due to their wide differential, complex anatomical and physiological implications, as well as the potential for widespread invasion in the case of malignancies. This review synthesizes recent findings surrounding the diagnosis and management of specifically right-sided cardiac tumours, with a particular focus on surgical resection and reconstructive techniques.
Recent Findings: Management of cardiac tumours can be categorized into three key phases.
Biomarkers.
Alzheimers Dement
December 2024
Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.
Background: The present study aimed to establish a panel of plasma proteins that are associated with cognitive performance and amyloid-β burden and establish their utility for distinguishing early Alzheimer's disease (AD) from healthy controls.
Method: Plasma from fifty patients with early AD (all amyloid-positive) and forty-nine healthy controls (HCs) were assayed using quantitative mass spectrometry. The weighted correlation network analysis (WGCNA) was used to explore the association between plasma protein levels and cognitive performance and filter out the high-performance plasma proteomic biomarker candidates.
Biomarkers.
Alzheimers Dement
December 2024
Thai Red Cross Emerging Infectious Diseases Health Science Centre, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Alzheimer's disease (AD) is referred as one of the most common causes of dementia and frailty. To address this impending public health crisis, there is a critical need to identify simple and reliable biomarkers for early AD diagnosis. Recent research has highlighted the potential utility of salivary lactoferrin (Lf) as a promising biomarker for AD diagnosis.
View Article and Find Full Text PDFBackground: A lesson of the recent progress in Alzheimer's Disease therapy is that biomarker-driven trials will be crucial to demonstrating efficacy in the clinic. Many studies have demonstrated the potential predictive power of fluid and imaging biomarkers in guiding patient selection and continued progress of precision medicine approaches will demand development of multi-dimensional biomarker arrays. However, correlations between candidate biomarkers change non-linearly with time, requiring methodologies to align biomarkers across a common disease timescale (time from amyloid positivity; TFAP).
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Knight Alzheimer Disease Research Center, Saint Louis, MO, USA.
Background: With the traditional FDA approval of lecanemab for treatment of early symptomatic Alzheimer disease (AD), there has been a surge in demand for clinical AD biomarker testing. While amyloid PET, cerebrospinal fluid (CSF) biomarkers, and AD blood tests are all clinically available, each have different benefits and limitations affecting their real-world use.
Methods: Pragmatic issues affecting usage of different AD biomarker testing modalities have been experienced in a large specialty memory clinic in St.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!